Skip to main content
Erschienen in: Rheumatology International 3/2011

01.03.2011 | Original Article

Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression

verfasst von: Victoria Connor

Erschienen in: Rheumatology International | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Knowledge and understanding about the immunosuppressive properties of anti-TNF therapies and the adverse effects these causes have advanced over the last 10 years since the first of these drugs was approved. These drugs work by inhibiting tumour necrosis factor (TNF) in the body, which plays an essential role in the immune response to invading pathogens. Anti-TNF drugs have therapeutic value because high levels of TNF are thought to be part of the pathophysiology of many chronic inflammatory disorders such as rheumatoid arthritis and Crohn’s disease. Anti-TNF drugs are usually well-tolerated, however, there have been reports of many potentially serious adverse effects. This article will comprehensively analyse these adverse effects; the incidence, symptoms and mechanisms will be discussed. In addition, the contraindications of this class of drugs will be explored and the detection and prevention methods that should be put in place by health care professionals who treat patients on these drugs will be described.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Atzeni F, Sarzi-Puttini P (2008) Autoantibody production in patients treated with anti-TNF-α. Expert Rev Clin Immunol 4(2):275–280CrossRefPubMed Atzeni F, Sarzi-Puttini P (2008) Autoantibody production in patients treated with anti-TNF-α. Expert Rev Clin Immunol 4(2):275–280CrossRefPubMed
2.
Zurück zum Zitat Deepe GS Jr, Wallis RS (2006) Tumor necrosis factor-α inhibitors and granulomatous infectious. Drug Discov Today Dis Mech 3(2):295–300CrossRef Deepe GS Jr, Wallis RS (2006) Tumor necrosis factor-α inhibitors and granulomatous infectious. Drug Discov Today Dis Mech 3(2):295–300CrossRef
3.
Zurück zum Zitat Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350(21):2167–2179, 2226 Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350(21):2167–2179, 2226
4.
Zurück zum Zitat Wallis RS (2008) Tumor necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8(10):601–611CrossRefPubMed Wallis RS (2008) Tumor necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8(10):601–611CrossRefPubMed
5.
Zurück zum Zitat Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 42(5):617–621CrossRefPubMed Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 42(5):617–621CrossRefPubMed
6.
Zurück zum Zitat Furst DE, Wallis R, Broder M, Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36(3):159–167CrossRefPubMed Furst DE, Wallis R, Broder M, Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36(3):159–167CrossRefPubMed
7.
Zurück zum Zitat Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34(5 SUPPL):34–38CrossRefPubMed Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34(5 SUPPL):34–38CrossRefPubMed
8.
Zurück zum Zitat Callen JP (2007) Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 26(1):6–14CrossRefPubMed Callen JP (2007) Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 26(1):6–14CrossRefPubMed
9.
Zurück zum Zitat Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clinl Exp Rheumatol 20(6 Suppl 28):S152–S157 Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clinl Exp Rheumatol 20(6 Suppl 28):S152–S157
10.
Zurück zum Zitat Weinberg JM, Buchholz R (2006) TNF-alpha inhibitors, 1st edn. Birkh©Þuser Verlag, Basel Weinberg JM, Buchholz R (2006) TNF-alpha inhibitors, 1st edn. Birkh©Þuser Verlag, Basel
12.
Zurück zum Zitat Desai SB, Furst DE (2006) Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 20(4):757–790CrossRefPubMed Desai SB, Furst DE (2006) Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 20(4):757–790CrossRefPubMed
14.
Zurück zum Zitat Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor an antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44(9):1977–1983CrossRefPubMed Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor an antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44(9):1977–1983CrossRefPubMed
16.
Zurück zum Zitat Lee SJ, Kavanaugh A (2005) Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol 116(4):900–905CrossRefPubMed Lee SJ, Kavanaugh A (2005) Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol 116(4):900–905CrossRefPubMed
17.
Zurück zum Zitat Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG (2008) Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol 20(3):327–333CrossRefPubMed Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG (2008) Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol 20(3):327–333CrossRefPubMed
18.
Zurück zum Zitat Balakumar P, Singh M (2006) Anti-tumor necrosis factor-α therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 99(6):391–397CrossRefPubMed Balakumar P, Singh M (2006) Anti-tumor necrosis factor-α therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 99(6):391–397CrossRefPubMed
20.
Zurück zum Zitat Moots RJ, Taggart A, Walker D (2003) Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology 42(5):614–616PubMed Moots RJ, Taggart A, Walker D (2003) Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology 42(5):614–616PubMed
Metadaten
Titel
Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression
verfasst von
Victoria Connor
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 3/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1292-x

Weitere Artikel der Ausgabe 3/2011

Rheumatology International 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.